| Background&ObjectiveDiabetes mellitus is a chronic metabolic disease characterized by elevated plasma glucose levels. Type2diabetes mellitus accounted for90%～95%of all diabetes mellitus patients. With the prevalence of this disease gradually increasing, diabetes incidence rate has been reached up to9.7%in China, so the treatment of diabetic seems pluralistic and complex. At present, drugs in medicinal plants for curing diabetes are oral antidiabetic, insulin, GLP-1exogenous agonist, GLP-1analogues and so on in domestic and overseas. Because diabetes commonly combined with hypertension and dyslipidemia, clinical treatment sounds needing combination. So what about the state of the treatment status and rationality of drug use in T2DM? In order to solve these problems and provide guidance for clinical medication, this study has been designed.Methods1.Data were collected from type2diabetes mellitus who were admitted in-patient and out-patient department in Henan Provincial People’s Hospital from Oct. 2010to Dec.2012. Totally1192subjects (male803, female389) with complete material were analyzed in this article.2.Log on:the specialists filled in forms of unified design, strictly quality controlled standards had been carried out in data collection, processing, clinical examination and laboratory investigations.3.Registry contents:Hypoglyceimic agents, lipid-lowering and antihypertensive agents had been checked in while the patients entered the hospital. Related factors include:gender, age, duration, history of smoking, drinking history, BMI, hypertension, Plasma Insulin, HbAlc and dyslipidemia had been registered.4.Through the prevalence of cross-sectional analysis of HbA1C and plasma insulin levels, we had got knowledge of blood sugar control situation, complications and islet function in Type2Diabetes.5.The data were analyzed by SPSS17.0.Results1.In Cross-sectional analysis, the prevalence of chronic complications in T2DM patients results for:Nephropathy was50.1%, peripheral neuropathy was40.6%, retinopathy was35.2%, coronary heart disease was24.6%, autonomic neuropathy was16.5%, and cerebrovascular disease was14.2%.2.Drug therapy:Oral antidiabetic was48.5%, among the rest separate drug use not united was31.3%, drug use united with two or more was17.2%; Insulin administration was43.4%, Insulin alone was11.2%, Insulin joint orally was32.2%. The rate of none used drugs cases was4.1%, among the rest diet and exercise therapy was2.5%. Blood sugar control condition:mean of HbAlc was8.6±1.9(%), HbA1c less than6.5%was21.6%, HbAlc less than7%was35.9%.3.Hypertension was58.0%. In the hypotensive drugs, separate drug use not united was59.2%, among the rest the most application was CCB(31.9%); in combination therapy,3kinds of application drug combinations was ARB+CCB (31.9%), more than3kinds of application drug combinations was0.8%.Not use drugs was9.9%. Blood pressure control success rate was48.9%. 4.Dyslipidemia was57.5%. In the dyslipidemia treatment drug, statins was55.7%, fibrates was3.1%, not used drugs was41.2%. Dyslipidemia control success rate was26.7%.5.Gender, age, duration, BMI, history of smoking and insulin resistance index was the main influencing factors to cause T2DM high blood pressure and dyslipidemia.6.The cases with high blood pressure or dyslipidemia group had obvious insulin resistance.Conclusions1.T2DM with high blood pressure and in the prevalence of dyslipidemia was high, which was related with gender, age, duration, BMI, history of smoking and insulin resistance index relevant.2.Blood sugar lipid control success rate is low3.In Cross-sectional analysis, chronic complications morbidity was high, the highest prevalence of which was diabetic nephropathy among the study. |
PDF Full Text Request